You are here: Industry Insights > Orencia

News List

First drug for acute graft-versus-host disease prevention approved by FDA EuropeanPharmaceuticalReview
December 23, 2021
BMS’s Orencia (abatacept) has been approved by the US FDA for prophylaxis of acute graft-versus-host disease (aGvHD) in patients aged two years plus.
FDA Approves Orencia in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Graft Versus Host Disease AmericanPharmaceuticalReview
December 17, 2021
Bristol Myers Squibb announced that Orencia® (abatacept) was approved by the FDA for the prophylaxis, or prevention, of acute graft versus host disease (aGvHD), in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and...
FDA Approves First Drug to Prevent Graft Versus Host Disease FDA
December 16, 2021
Today, the U.S. Food and Drug Administration approved Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease (aGVHD), a condition that occurs when donor bone marrow or stem cells attack the graft recipient...
BMS 2Q Revenues up 16% contractpharma
August 02, 2021
Top sellers Revlimid, Eliquis and Opdivo drive growth while established brands were down 64%.
BMS’ Orencia gets breakthrough status in US to prevent GvHD pharmaceutical-technology
December 09, 2019
Bristol-Myers Squibb (BMS) has received breakthrough device designation for its Orencia (abatacept) drug to prevent moderate to severe acute graft-versus-host disease (GvHD).